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The World Health Organisation (WHO) Classification of Tumours series, published as the 
WHO Blue Books (Figure 1) and the accompanying website, are essential resources for 
pathologists across the globe, providing the standards against which tumours are classified to 
aid cancer diagnosis, research, treatment and prognosis. Each book tackles the classifications 
of up to 300 tumour types, defining for each of these the etiology, pathogenesis, epidemiology, 
clinical features, macroscopic appearances, histology, cytology, molecular pathology, 
essential and desirable diagnostic features, staging, prognostic factors, and predictive 
biomarkers. If each tumour were to require one formal review, this would mean finding or 
conducting up to 3,600 such reviews for each book which would not be practicable or time 
efficient. The current approach therefore relies largely on subject experts drawing on published 
literature searches according to their individually perceived need to inform the content of these 
books. However, these decisions affect the classification, and hence the diagnosis and 
management of cancer patients worldwide. Consequently, to minimise the risk of including 
biased information, the evidence is weighed and decisions made by an editorial board. This 
editorial board is composed of standing members and content experts (mainly practicing 
pathologists) who meet, propose, revise and agree on definitions and core criteria for each 
tumour systematically for every new edition.  
 
Over-reliance on expert consensus at editorial board meetings for this purpose may lead to 
problems (Table 1). Firstly, evidence needs to be reviewed in order to assess all relevant 
issues in a WHO Blue Book. But, even if all participating experts are required to perform 
literature reviews, their different expertise and inevitable time constraints produce variable 
results with potential for studies that are relevant to decisions to be missed. In the first book 
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of the new 5th edition, up to 130 tumours or subjects were described as “unknown” and 200 
labelled as clinically not relevant, this often being the only description of a whole section(1). 
Sections such as etiology or pathogenesis are frequently summarized as “unknown”, without 
providing more details, leaving unclear whether an exhaustive search of the literature has 
been performed.  This does not necessary indicate that systematic reviews should be routinely 
performed when such questions arise and indeed it would not be possible for standing 
members and content experts to do so given the number that would be required. Often the 
statements requiring evidence are more related to background information than issues 
relevant to classification, and introducing systematic approaches to the literature searches 
would not improve the evidence 
 
 
base of the review results. In addition, this would allow authors to focus on the pressing or 
contentious issues of tumour classification: topics that need to be assessed by systematic 
reviews, due to their potential controversy. Secondly, there is a potential risk that unintended 
bias from content experts could influence decisions in the absence of a structured and 
controlled process of evidence synthesis. This could lead to certain studies being unduly 
highlighted or overlooked depending on who is reviewing the literature and what their own 
clinical or research knowledge may be(2). Thirdly, if the convened expert panel is not 
sufficiently representative(3), skewed decisions may be made, which may not be fully informed 
by the best and most relevant evidence(4). Fourthly, due to interpersonal and cultural 
differences among experts during meetings, it is possible for individuals to dominate 
discussion(3, 5, 6). Finally, previously included but incorrectly referenced evidence may be 
carried forward during the updating process . 
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It is possible that these problems could be mitigated by the addition of evidence-based 
practices to the editorial process. Systematic reviews are widely regarded as the cornerstone 
of evidence-based medicine, encouraging comprehensive literature searching, transparency 
in methods and rigorous study appraisal(7). Performing systematic reviews for some tumour 
types could certainly improve the reliability of decisions taken by the editorial board, but they 




Systematic reviews require training in methods, as well as expertise (8-10). They can be 
laborious to complete, time-consuming and difficult to interpret, particularly when there is lot 
of evidence, or when the evidence is low-grade. Systematic review methods have been 
described as being formulaic(11, 12).  Best practice guidelines such as Cochrane(13) and 
PRISMA(14) are closely aligned with meta-analytic reviews for medical interventions, the 
methods of which are not necessarily appropriate to pathology. Systematic reviews can be 
long and unwieldy documents, difficult to interpret and hollow in their conclusions(15, 16). The 
hierarchy of evidence-based medicine with systematic reviews at the apex has been resisted 
by some academic groups and clinicians for oversimplifying complex issues relating to clinical 
care(17). Some argue that clinical judgement based on experience is more exact and applies 
better to real life clinical situations, because of its emphasis on individual cases rather than 
evidence derived from randomised controlled trials (RCT) that are produced without social and 
political confounding effects and of other variables(18). Whilst the scientific rigour of 
systematic reviews and indeed RCTs are preserved through adhering to reporting guidelines, 
they have been shown to be less readable than article types which allow some spin or 
journalistic creativity, such as editorials and narrative reviews(19). They are also subject to 
influence if not conducted objectively and not properly assessed prior to publication(20). 
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Managing the influence and expertise of team members in systematic reviews, like non-




Although essential for the synthesis of available scientific evidence in controversial questions, 
it is clear that systematic review methods would need to be adapted to the specific needs of 
the WHO Classification of Tumors and its editorial process. Timely procurement of a valid 
evaluation of evidence is one of the major problems for process-driven systems such as the 
WHO Classification of Tumors, and this is something that traditional, comprehensive 
systematic reviews struggle to provide. More succinct review methods including, mapping, 
rapid or scoping reviews could improve the quality of scientific evidence used to make 
statements in the WHO Blue Books, without the need for full systematic reviews(21-23). While 
alternative methods that abbreviate systematic reviews may be appealing, they do increase 
the risk of bias and errors in the review process and may not always provide the expected 
results(21, 22, 24). Careful assessment of the need for evidence synthesis may show that a 
structured expert description of the subject is enough. We believe that full systematic reviews 
of the available evidence should be limited to the assessment of research questions that 
directly affect the classification of a tumour, or have major consequences in cancer diagnosis. 
 
Nowhere is the need to consider consensus-based versus evidence-based approaches more 
apparent than in the field of molecular pathology, where research groups may suggest 
different molecular tumor classifications for the same tumor type.  In these instances, 
evidence synthesis and evaluations to underpin incorporation of molecular advances into the 
classification will be greatly assisted by the use of the Standards for Reporting Diagnostic 
Accuracy Studies (STARD)(25), Transparent Reporting of a Multivariable Prediction Model for 
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www.equator.net).    
 
Herein lies the challenge for the WHO Classification of Tumours, currently published as a 
series of 15 WHO Blue Books, and now as a website. Should it continue to rely primarily on 
experts without formal systematic review methods, or should it take steps to incorporate 
systematic reviews and/or adapted methods into the process of using expert consensus? The 
importance of systematic reviews and expert interpretation do not need to be viewed as 
mutually exclusive. Mickenautsch argues that to view one as superior to another is erroneous 
as each represent necessary concepts of analysis and synthesis(27).  Indeed, there is an 
opportunity to ensure that reviews are fit for purpose without enforcing rigid guidelines which 
can result in review products which are overly detailed and unwieldy to interpret(15). We 
propose an approach that is adapted to the needs of WHO Blue Books which requires authors 
to employ a series of ‘non-negotiables’ when performing the literature reviews that feed into 
key decisions for the WHO Blue Book series. They are: 
 
1. Transparency: clearly stated, pre-specified methods are critical and should be 
described in detail to assure reproducibility and reliability of the process. A publicly 
available protocol setting out the intended methods and eligibility criteria would help 
receiving external input into the review and facilitate updating. 
 
2. Searching rigor: at least two relevant bibliographic sources should be searched for 
relevant literature 
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3. Double checking: a proportion of randomly selected study selection and data extraction 






4. Risk of bias assessment: included individual studies should be assessed using 
standardised or adapted tools that consider areas of bias to which studies of pathology 
may be prone. Assessment of the body of the collected evidence may be useful, 
ranking it using validated criteria. 
 
Detail on the rationale and risk underlying each ‘non-negotiable’ are outlined in Table 2. The 
issue of using validated methods for WHO classification of tumours is becoming increasingly 
important because, due to rapid advances in molecular pathology, more information is 
becoming evident from closer analysis of tumours than was previously available from 
histopathological analysis alone. Systematic review methods may need to be adapted to 
assess this information, as some steps of a validated systematic review process may not meet 
current need, or simply not add sufficient value to the editorial process. 
 
Not every decision made in the WHO Classification of Tumours is contentious; many areas 
may be regarded as close to fact due to strong logic or pathophysiological basis: they can be 
considered as equivalent of parachutes – known to be efficacious without the need to conduct 
a RCT(28). However, when issues are debatable or likely to vary depending on context or 
interpretation then a systematic review may be deemed necessary. An example of this occurs 
with Kaposi’s sarcoma where there is some debate over whether the characteristic tumours 
can reliably be regarded as neoplasms or as a “reactive” proliferations of cells in response to 
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infections with Human Herpesvirus-8 (HHV-8)(29). Cancerous tumours are commonly 
regarded to be clonal neoplasms which proliferate uncontrollably, even after the stimulus 
which evoked the change has been removed(30), Kaposi sarcoma is contentious because 
there are cases where it does not persist following successful antiretroviral treatment(31). 
However, reclassification of Kaposi sarcoma could have ramifications for patient diagnosis 
and care, as well as service delivery and funding for research. In response to this dilemma, a 
systematic review protocol was designed and registered prospectively by the WHO tumour 
classification group on the PROSPERO database (CRD42018087595). The review aims to 
inform and support the decision of the expert panel regarding Kaposi Sarcoma classification 




There are challenges for the classification of tumours in evidence-based pathology. Differing 
evidence levels and considerations are applied within the field of pathology and consensus is 
needed to promote a comparable assessment of studies. Review methods should allow 
reliable assessments of evidence in an appropriate time frame and without being systematic 
review methodologists. Experts who serve as authors and editors require basic training and 
methodological support in systematic review and literature searching methods. Furthermore, 
subjects in need of assessment should be registered and prioritized based on WHO 
Classification of Tumours requirements and scientific considerations. The WHO Classification 
of Tumours Group at the International Agency for Research on Cancer (IARC) have set 
themselves the challenge to revise their procedures to incorporate systematic review methods 
into the current expert-led approach through the appointment of a systematic reviewer for the 
Blue Books and by planning an international Joint Action Group. The methods described here 
aim to start this deliberation and we invite discussion and feedback as to the potential 
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challenges and solutions to the intended “non-negotiables” proposed to ensure the methods 




In conclusion, we believe that an evidence-based approach to informing key decisions that 
feed into tumour classification would allow editors to mitigate any potential risks of bias and 
also benefit authors by providing structured, transparent and reliable methods for the synthesis 
of available evidence for each tumour type. Our hope over time is that this approach will 
increase the rigour of the decisions feeding into WHO tumour classification, by addressing 
critical questions and identifying research gaps, as well as reaching recommendations for 
research to inform future editions. Such an approach will help maintain the reliability of tumour 
classification, and help to provide solutions to challenges like the exponential rise in number 
of scientific publications and the need to manage new types of information such as evidence 
from genetics or big data.  
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Table 1: Problem arising from consensus based approach and proposed solutions by 
an evidence-based approach
Problem of a consensus 
based approach 
Solution by an evidence-
based approach  
Potential problems not 
solved by an evidence-
based approach
Risk of missing relevant research Comprehensive searching which is 
part of systematic reviewing may 
improve identification of important 
literature.
A structured, systematic process 
allows summarizing and evaluating 
complex information such as big data 
or basic research information 
provided for molecular pathology.
Risk of missing research 
which does not fit into 
standard study design 
framework used for 
systematic reviews.
Publication bias may not be 
addressed if only searching 
published evidence.
Selection of the literature may be 
biased
Systematic reviews require clearly 
stated inclusion criteria, so cherry 
picking of particular studies to prove 
a particular point is easier to spot. 
In addition, the setting of acceptable 
evidence levels and assessment of 
risk of bias of studies avoids the use 
of inappropriate evidence.
Presentation of results may 
still allow a certain degree of 
“cherry picking” when 
presenting only on selected 
outcomes (Outcome reporting 
bias).
Interpretation of the literature may 
be biased
Systematic reviews consider each 
included study equally, unless there 
is a specific reason why less 
emphasis should be placed on it 
such as small sample or poor study 
quality.
Risk of bias assessment of individual 
studies, but also of the body of 
evidence can be undertaken to aid 
an appropriate interpretation of the 
retrieved evidence.
The use of several reviewers 
may not provide the desired 
control of bias effect and 
instead interesting 
information, may not be 
incorporated due to 
disagreement.
Panel of experts may be biased in 
composition or be dominated by 
particular individuals
A systematic review with clear 
eligibility criteria made available in a 
protocol may provide a reference 
point against which “extreme” views 
by particular panel members can be 
mitigated. 
Panel may still be biased in 
developing eligibility criteria, 
even if an evidence-based 
approach helps in the 
discussion.
Difficulties in documentation of 
included evidence (especially in the 
updating process)
Systematic review protocol and 
reports document the biomedical 
databases searched and over what 
time period therefore uncertainty 
about whether a particular study has 
been included or not is much less 
likely to occur. 
Relies on the well-designed 
and appropriate literature 
searches and implementation 
of reporting standards for 
systematic reviews.
Credibility of classification may be 
undermined if not evidence-based
Use of systematic review methods 
will improve the credibility of the 
classification, as well as the reliability 
of tumour classification. 
Credibility may also be 
affected by other factors not 
addressed by a systematic 
review process.
Experts in the field, important 
to the credibility of the books, 
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Table 2. Methodological non-negotiables for systematic reviews for the purposes of 
tumour classification
Rationale Risks (if not considered in the review)
1. Transparency
Methods should be clearly stated and previously 
defined. Inclusion and exclusion criteria stated and 
applied.
A review protocol should be written and made publicly 
available as an explicit statement of intended 
methods where deviations to these methods can be 
noted (with justifications). This ensures accountability 
by authors and facilitates replication of the review.
Conflict of interests of the review team, as well as 
funding information needs to be disclosed.
 Methods may not be appropriate to ensure 
equitable representation of literature globally 
 Unjustified deviations to planned methods remain 
unchallenged.
 Undeclared conflicts of interest or researcher 
allegiance from authors may influence 
conclusions
2. Searching rigor
Searching two major bibliographic databases, (e.g. 
PubMed and Web of Science), minimises the chance 
that a highly relevant study will be missed. Whilst 
there are overlaps in medical bibliographic databases, 
indexing varies considerably. Therefore searching 
only one database means that retrieval of relevant 
literature is highly dependent on 
appropriateness/accuracy of the search strategy.
 Reliance on one database capturing all relevant 
studies, reliance on all relevant studies being 
accurately indexed and reliance on a single 
search strategy being sufficient to capture all 
relevant literature
 Failure to identify all relevant literature
3. Double checking
Duplication of the data extraction and a proportion of 
the total study selection done by the primary author 
should be completed by a second reviewer for 
accuracy. Where multiple discrepancies are noted, 
further checking may be required for consistency.
 Reliance on the accuracy and consistency of one 
author for all study selection and data extraction
 Bias in selection of studies
 Greater chance of erroneous study selection or 
data extraction
4. Risk of bias assessment
A methodological quality assessment tool for 
pathology reviews should be adapted, based on 
standardized risk of bias assessment tool. This helps 
review authors to assign more weight to findings from 
studies of higher quality or at lower risk of bias in 
interpretation.
 No objective method of appraising studies for 
higher risk of bias
 Biases from primary studies are perpetuated in 
the review
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